Loading…

Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes

Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of invasive cardiology 2010-01, Vol.22 (1), p.40-44
Main Author: Alagona, Jr, Peter
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 44
container_issue 1
container_start_page 40
container_title The Journal of invasive cardiology
container_volume 22
creator Alagona, Jr, Peter
description Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy with aspirin, clopidogrel, and/or glycoprotein (GP) IIb/IIIa inhibitors. Despite the comprehensive nature of current guidelines, several important clinical issues concerning the optimal initiation of antiplatelet therapy remain. This review addresses four of these clinical issues: When should GP IIb/IIIa inhibitors be initiated? When should clopidogrel be initiated? What is the optimal clopidogrel loading dose? How should antiplatelet therapy be approached in chronically anticoagulated patients?
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733928341</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733928341</sourcerecordid><originalsourceid>FETCH-LOGICAL-p210t-4ee3a8b5a30c808939166e4bd10f1732bb0b865f0684fa8a92dd1481027e460e3</originalsourceid><addsrcrecordid>eNo1kE1LxDAYhIMg7rr6FyQ3T4U3H23Toyx-wYIX91zS9i0bSZOapEr_vRHX08DwMMzMBdmysqwLXgLbkOsYPwA4Ew27IhsOIJVomi0Zjy5g9PYLB2piXDBSHaPvjU7Z-TbpRFEHu1LjTMqm8Y76kWqXzGwzYzHRdMKg51-E6n5JSHsfvNNhpXF1Q_ATxhtyOWob8fasO3J8enzfvxSHt-fX_cOhmDmDVEhEoVVXagG9AtXktlWFshsYjKwWvOugU1U5QqXkqJVu-DAwqRjwGmUFKHbk_i93Dv4zj0ntZGKP1mqHfoltLUTDlZAsk3dncukmHNo5mClXbv-vET91iWC2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733928341</pqid></control><display><type>article</type><title>Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes</title><source>Freely Accessible Journals</source><creator>Alagona, Jr, Peter</creator><creatorcontrib>Alagona, Jr, Peter</creatorcontrib><description>Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy with aspirin, clopidogrel, and/or glycoprotein (GP) IIb/IIIa inhibitors. Despite the comprehensive nature of current guidelines, several important clinical issues concerning the optimal initiation of antiplatelet therapy remain. This review addresses four of these clinical issues: When should GP IIb/IIIa inhibitors be initiated? When should clopidogrel be initiated? What is the optimal clopidogrel loading dose? How should antiplatelet therapy be approached in chronically anticoagulated patients?</description><identifier>EISSN: 1557-2501</identifier><identifier>PMID: 20048399</identifier><language>eng</language><publisher>United States</publisher><subject>Acute Coronary Syndrome - drug therapy ; Aspirin - therapeutic use ; Dose-Response Relationship, Drug ; Humans ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists &amp; inhibitors ; Ticlopidine - analogs &amp; derivatives ; Ticlopidine - therapeutic use ; Time Factors</subject><ispartof>The Journal of invasive cardiology, 2010-01, Vol.22 (1), p.40-44</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20048399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alagona, Jr, Peter</creatorcontrib><title>Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes</title><title>The Journal of invasive cardiology</title><addtitle>J Invasive Cardiol</addtitle><description>Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy with aspirin, clopidogrel, and/or glycoprotein (GP) IIb/IIIa inhibitors. Despite the comprehensive nature of current guidelines, several important clinical issues concerning the optimal initiation of antiplatelet therapy remain. This review addresses four of these clinical issues: When should GP IIb/IIIa inhibitors be initiated? When should clopidogrel be initiated? What is the optimal clopidogrel loading dose? How should antiplatelet therapy be approached in chronically anticoagulated patients?</description><subject>Acute Coronary Syndrome - drug therapy</subject><subject>Aspirin - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Humans</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists &amp; inhibitors</subject><subject>Ticlopidine - analogs &amp; derivatives</subject><subject>Ticlopidine - therapeutic use</subject><subject>Time Factors</subject><issn>1557-2501</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNo1kE1LxDAYhIMg7rr6FyQ3T4U3H23Toyx-wYIX91zS9i0bSZOapEr_vRHX08DwMMzMBdmysqwLXgLbkOsYPwA4Ew27IhsOIJVomi0Zjy5g9PYLB2piXDBSHaPvjU7Z-TbpRFEHu1LjTMqm8Y76kWqXzGwzYzHRdMKg51-E6n5JSHsfvNNhpXF1Q_ATxhtyOWob8fasO3J8enzfvxSHt-fX_cOhmDmDVEhEoVVXagG9AtXktlWFshsYjKwWvOugU1U5QqXkqJVu-DAwqRjwGmUFKHbk_i93Dv4zj0ntZGKP1mqHfoltLUTDlZAsk3dncukmHNo5mClXbv-vET91iWC2</recordid><startdate>201001</startdate><enddate>201001</enddate><creator>Alagona, Jr, Peter</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201001</creationdate><title>Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes</title><author>Alagona, Jr, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p210t-4ee3a8b5a30c808939166e4bd10f1732bb0b865f0684fa8a92dd1481027e460e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acute Coronary Syndrome - drug therapy</topic><topic>Aspirin - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Humans</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists &amp; inhibitors</topic><topic>Ticlopidine - analogs &amp; derivatives</topic><topic>Ticlopidine - therapeutic use</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alagona, Jr, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of invasive cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alagona, Jr, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes</atitle><jtitle>The Journal of invasive cardiology</jtitle><addtitle>J Invasive Cardiol</addtitle><date>2010-01</date><risdate>2010</risdate><volume>22</volume><issue>1</issue><spage>40</spage><epage>44</epage><pages>40-44</pages><eissn>1557-2501</eissn><abstract>Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy with aspirin, clopidogrel, and/or glycoprotein (GP) IIb/IIIa inhibitors. Despite the comprehensive nature of current guidelines, several important clinical issues concerning the optimal initiation of antiplatelet therapy remain. This review addresses four of these clinical issues: When should GP IIb/IIIa inhibitors be initiated? When should clopidogrel be initiated? What is the optimal clopidogrel loading dose? How should antiplatelet therapy be approached in chronically anticoagulated patients?</abstract><cop>United States</cop><pmid>20048399</pmid><tpages>5</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1557-2501
ispartof The Journal of invasive cardiology, 2010-01, Vol.22 (1), p.40-44
issn 1557-2501
language eng
recordid cdi_proquest_miscellaneous_733928341
source Freely Accessible Journals
subjects Acute Coronary Syndrome - drug therapy
Aspirin - therapeutic use
Dose-Response Relationship, Drug
Humans
Platelet Aggregation Inhibitors - therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Time Factors
title Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A33%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unresolved%20issues%20associated%20with%20early%20initiation%20of%20antiplatelet%20therapy%20in%20acute%20coronary%20syndromes&rft.jtitle=The%20Journal%20of%20invasive%20cardiology&rft.au=Alagona,%20Jr,%20Peter&rft.date=2010-01&rft.volume=22&rft.issue=1&rft.spage=40&rft.epage=44&rft.pages=40-44&rft.eissn=1557-2501&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E733928341%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p210t-4ee3a8b5a30c808939166e4bd10f1732bb0b865f0684fa8a92dd1481027e460e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733928341&rft_id=info:pmid/20048399&rfr_iscdi=true